Results 151 to 160 of about 516,619 (288)

Functional Characteristics Derived from the Structural Design of Bispecific Antibodies. [PDF]

Pharmaceuticals (Basel)
Han J, Lim SY, Kim Y, Jeong D, Kim HO, Ha SJ, Park JA, Won YW, Lim KS.   +8 more
europepmc   +1 more source

SKY92 Identifies High‐Risk Newly Diagnosed Multiple Myeloma With Inferior Progression‐Free Survival and Implicates NUF2 as a Candidate Driver

European Journal of Haematology, EarlyView.
ABSTRACT Objectives To determine the prevalence and prognostic significance of the SKY92 gene‐expression signature, evaluate minimal/measurable residual disease (MRD), and identify molecular drivers of high‐risk disease in transplant‐eligible newly diagnosed multiple myeloma (TE‐NDMM) patients in the Republic of Ireland.
Roisin M. McAvera, Izabela Cymer, John Quinn, Phillip T. Murphy, Patrick Thornton, Niamh McAuley, Harmony Black, Omar Abdelzaher, Catherine Duane, Tatiana Cichocka, Eva Szegezdi, Meegahage Perera, Gerard M. Crotty, Michelle Connolly, Aileen Walsh, Ruth Clifford, Janusz Krawczyk, Teresa Meenaghan, Vitaliy Mykytiv, Ezzat Elhassadi, Mark Coyne, Robert J. Cummins, Rowan Kuiper, Michael O'Dwyer, Siobhan V. Glavey   +24 more
wiley   +1 more source

Cytolysis of leukemic B-cells by T-cells activated via 2 bispecific antibodies

, 1993
Bispecific monoclonal antibodies can be used in the activation of effector cells to lyse autologous tumor cells. We analyzed the activation of human T-cells in vitro with bispecific monoclonal antibodies, which were generated by hybridoma-hybridoma ...
von Fliedner, V., Tesch, H., Manzke, O., Bohlen, H., Doerken, B., Moldenhauer, G., Diehl, V., Patel, B.   +7 more
core  

Safety and efficacy of bispecific antibodies in hematologic neoplasms: a systematic review. [PDF]

Front Immunol
Lommuang K, Taychakhoonavudh S.
europepmc   +1 more source

InflaMix Predicts Severe CRS, ICU Admission, and Progression‐Free Survival After CAR‐T Therapy in LBCL

European Journal of Haematology, EarlyView.
ABSTRACT Objectives Baseline systemic inflammation has emerged as a determinant of outcome after CD19‐directed CAR‐T therapy. We evaluated the prognostic performance of the recently developed INFLAmmation MIXture Model (InflaMix) in an independent bicentric cohort of patients with large B‐cell lymphoma (LBCL) receiving commercial CAR‐T cells, focusing ...
Eugenio Galli, Daniele Mannina, Alessandro Corrente, Chiara De Philippis, Ilaria Pansini, Marcello Viscovo, Stefan Hohaus, Patrizia Chiusolo, Federica Sorà, Stefania Bramanti, Simona Sica   +10 more
wiley   +1 more source

Bispecific Antibodies for Glomerular Diseases: Are We Ready for Prime Time? [PDF]

J Am Soc Nephrol
Karam S, Boudhabhay I, Jhaveri KD.
europepmc   +1 more source

A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

British Journal of Haematology, EarlyView.
Runfeng Zhang, Hong Yu, Miao Chen, Xiaoqi Qin, Jie Xiao, Yun Leng, Mingzhe Zhao, Jie Yu, Chunjie Qin, Xiuju Wang, Jingcheng Zhang, Wei Wang, Wenming Chen, Yanping Ma, Rong Fu, Junling Zhuang   +15 more
wiley   +1 more source

Transplantation Strategies in Treatment of Primary Plasma Cell Leukemia in Germany—A Multi‐Center Analysis

European Journal of Haematology, EarlyView.
ABSTRACT Objectives Primary plasma cell leukemia (pPCL) is a rare disease with poor outcomes. As data on randomized phase‐III trials are lacking, treatment recommendations are predominately based on retrospective analyses incorporating time periods with outdated therapies. Thus, the optimal consolidation strategy remains to be defined.
Maria Dampmann, Sarah Flossdorf, Julius Keyl, Theo Leitner, Cyrus Khandanpour, Markus Maulhardt, Evgenii Shumilov, Matthias Stelljes, Lisa Leypoldt, Marie Harzer, Christoph Schaefers, Francis Ayuketang Ayuk, Bastian von Tresckow, Amelie Boquoi, Thomas Schroeder, Hans Christian Reinhardt, Christine Hanoun   +16 more
wiley   +1 more source

Bispecific Antibodies and Antibody-Drug Conjugates in Advanced Gastric Adenocarcinoma. [PDF]

Cancers (Basel)
Rogers JE, Ajani JA.
europepmc   +1 more source

Outcomes of refractory and early‐relapsed large B‐cell lymphoma patients after first‐line treatment in the prospective Real‐world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre‐CAR T era

British Journal of Haematology, EarlyView.
Stéphanie Guidez, Aurélien Belot, Fanny Cherblanc, Bastien Lesné, Sylvain Carras, Catherine Thieblemont, Fontanet Bijou, Cédric Rossi, Luc Mathieu Fornecker, Jehan Dupuis, Krimo Bouabdallah, Ludovic Fouillet, Adrien Chauchet, Benoit Tessoulin, Loic Ysebaert, Alice Pauc, Pascale Cony‐Makhoul, Remy Gressin, Gaelle Laboure, Antoine Bonnet, Sandy Amorim, Christophe Fruchart, Roch Houot, Gian Matteo Pica, Carole Soussain, Sophie Dennetiere, Cécile Leyronnas, Pauline Lionne‐Huyghe, Hervé Ghesquières, Pierre Sesques   +29 more
wiley   +1 more source